OTCMKTS:PBSV Pharma-Bio Serv - PBSV Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharma-Bio Serv, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.00 +0.06 (+6.38%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.94▼$1.0050-Day Range$0.80▼$1.1752-Week Range$0.58▼$1.20Volume12,262 shsAverage Volume11,304 shsMarket Capitalization$22.97 millionP/E Ratio20.00Dividend YieldN/APrice TargetN/A ProfileChartCompetitorsDividendEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort Interest About Pharma-Bio Serv (OTCMKTS:PBSV) StockPharma-Bio Serv, Inc. engages in the provision of technical compliance consulting service and microbiological and chemical laboratory testing services to the pharmaceutical, chemical, medical device and biotechnology industries. It operates through the following business segments: Puerto Rico Technical Compliance Consulting; United States Technical Compliance Consulting; and Europe Technical Compliance Consulting. The company was founded in February 1993 and is headquartered in Dorado, Puerto Rico.Read More Receive PBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter. Email Address PBSV Stock News HeadlinesMarch 24, 2023 | americanbankingnews.comPharma-Bio Serv, Inc. (PBSV) to Issue Dividend of $0.08 on April 14thMarch 22, 2023 | americanbankingnews.comEquities Analysts Issue Forecasts for Pharma-Bio Serv, Inc.'s Q3 2023 Earnings (OTCMKTS:PBSV)March 30, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 20, 2023 | finance.yahoo.comPBSV: A Steady Performer with Upside PotentialMarch 17, 2023 | finance.yahoo.comPharma-Bio Serv Announces Results for the Quarter Ended January 31, 2023March 7, 2023 | markets.businessinsider.com4 Analysts Have This to Say About BridgeBio PharmaMarch 3, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)February 21, 2023 | marketwatch.comBio Pharma Buffer Market 2023: Emerging Trends and Best Practices in Futurism till 2028March 30, 2023 | WealthPop (Ad)Adam Mesh: “This Strategy Saved My Trading Career”Adam Mesh was $50,000 in the hole - and ready to quit trading for good… Until he discovered the secret to unlocking double-digit income. This strategy has averaged 64% average gains in the last three years. Adam is hosting a free session to show ordinary folks how to execute this incredible strategy. Click here to let Adam show you how it’s done. February 16, 2023 | marketwatch.comBio Pharma Logistics Market Growth, Business Overview and Forecast to 2028February 14, 2023 | marketwatch.comBio Pharma Buffer Market Size, Share and Forecast 2028 with Top Countries DataFebruary 7, 2023 | finanznachrichten.dePharma-Bio Serv Inc.: Pharma-Bio Serv Retains Investment Banking Firm ACP Capital to Provide Investment Banking and M&A Advisory ServicesFebruary 7, 2023 | finance.yahoo.comPharma-Bio Serv Retains Investment Banking Firm ACP Capital to Provide Investment Banking and M&A Advisory ServicesFebruary 3, 2023 | finance.yahoo.comPBSV: Ready for Post-Pandemic GrowthFebruary 2, 2023 | marketwatch.comBio-Pharma Market Profiled Key Players to Show Impressive Revenue Growth by 2029February 1, 2023 | msn.comAGC Biologics in Bothell to produce new diabetes treatmentFebruary 1, 2023 | msn.comAGC Biologics in Bothell to produce new diabetes treatmentJanuary 30, 2023 | finance.yahoo.comPharma-Bio Serv Announces Full Year ResultsJanuary 26, 2023 | benzinga.comGlobal Bio analytical Testing Services Market to Surpass US$ 7,749.5 Million by 2030, Says Coherent Market Insights (CMI)January 19, 2023 | msn.comSun Pharma to buy US biotech firm for $576mnJanuary 18, 2023 | seekingalpha.comBridgeBio Pharma: The Hub-And-Spoke Model Is Complicated And ConfusingJanuary 9, 2023 | benzinga.comBANTAM PHARMACEUTICAL TO PRESENT AT BIOTECH SHOWCASE™ 2023January 7, 2023 | seekingalpha.comImmunityBio: Upcoming PDUFA, Solid Data, Confusing FinancesJanuary 4, 2023 | technews.tmcnet.comMassive Bio Announces Plans to Expand AI Use in Oncology, from Clinical Trial Matching to Drug Matching and BeyondNovember 18, 2022 | marketwatch.comThe Biopharma Report is one of the fastest-growing online newsletters focused on the pharmaceutical and biotechnology industry.November 2, 2022 | marketwatch.comBioactive Wound Care Market is Estimated to Accelerate Industry Development in Pharma & Healthcare Sector with Top Key Players till 2028October 22, 2022 | marketwatch.comBio Pharma Buffer Market Is Expected To Progress At A Fast Rate During Forecast 2022 To 2028See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharma-Bio Serv and its competitors with MarketBeat's FREE daily newsletter. Email Address PBSV Company Calendar Last Earnings1/30/2023Ex-Dividend for 4/14 Dividend3/28/2023Today3/30/2023Dividend Payable4/14/2023Fiscal Year End10/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Management consulting services Sub-IndustryN/A SectorBusiness Services Current SymbolOTCMKTS:PBSV CUSIPN/A CIK1304161 Webwww.pharmabioserv.com Phone(787) 278-2709Fax787-796-5168Employees190Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.05 Trailing P/E Ratio20.00 Forward P/E Ratio11.11 P/E GrowthN/ANet Income$1.01 million Net Margins6.05% Pretax Margin7.56% Return on Equity6.87% Return on Assets5.49% Debt Debt-to-Equity RatioN/A Current Ratio10.32 Quick Ratio10.32 Sales & Book Value Annual Sales$19.40 million Price / Sales1.18 Cash Flow$0.04 per share Price / Cash Flow25.50 Book Value$0.74 per share Price / Book1.35Miscellaneous Outstanding Shares22,970,000Free Float20,096,000Market Cap$22.97 million OptionableNot Optionable Beta0.32 Key ExecutivesVictor SanchezPresident & Chief Executive OfficerSandra MolinaDirector-Puerto Rico OperationsPedro J. LasantaCFO, Secretary & Vice President-AdministrationMiriam MarreroManager-Human ResourcesKey CompetitorsATIFNASDAQ:ATIFRyvylNASDAQ:RVYLAbri SPAC INASDAQ:ASPABIT MiningNYSE:BTCMAeroClean TechnologiesNASDAQ:AERCView All Competitors PBSV Stock - Frequently Asked Questions How have PBSV shares performed in 2023? Pharma-Bio Serv's stock was trading at $0.79 at the beginning of 2023. Since then, PBSV shares have increased by 26.6% and is now trading at $1.00. View the best growth stocks for 2023 here. How were Pharma-Bio Serv's earnings last quarter? Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) released its earnings results on Monday, January, 30th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $4.64 million for the quarter. Pharma-Bio Serv had a trailing twelve-month return on equity of 6.87% and a net margin of 6.05%. How often does Pharma-Bio Serv pay dividends? What is the dividend yield for Pharma-Bio Serv? Pharma-Bio Serv declared a dividend on Wednesday, March 22nd. Shareholders of record on Wednesday, March 29th will be given a dividend of $0.075 per share on Friday, April 14th. This represents a dividend yield of 7.75%. The ex-dividend date of this dividend is Tuesday, March 28th. Read our dividend analysis for PBSV. What other stocks do shareholders of Pharma-Bio Serv own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pharma-Bio Serv investors own include Zynerba Pharmaceuticals (ZYNE), Allena Pharmaceuticals (ALNA), AstroNova (ALOT), Oracle (ORCL), AT&T (T), Yintech Investment (YIN), Aeglea BioTherapeutics (AGLE), Ampliphi Biosciences (APHB), Carnival Co. & (CCL) and Earthstone Energy (ESTE). What is Pharma-Bio Serv's stock symbol? Pharma-Bio Serv trades on the OTCMKTS under the ticker symbol "PBSV." How do I buy shares of Pharma-Bio Serv? Shares of PBSV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pharma-Bio Serv's stock price today? One share of PBSV stock can currently be purchased for approximately $1.00. How much money does Pharma-Bio Serv make? Pharma-Bio Serv (OTCMKTS:PBSV) has a market capitalization of $22.97 million and generates $19.40 million in revenue each year. The company earns $1.01 million in net income (profit) each year or $0.05 on an earnings per share basis. How many employees does Pharma-Bio Serv have? The company employs 190 workers across the globe. How can I contact Pharma-Bio Serv? Pharma-Bio Serv's mailing address is Pharma-Bio Serv Building Suite 6 Road 696, DORADO PR, 00646. The official website for the company is www.pharmabioserv.com. The company can be reached via phone at (787) 278-2709, via email at scottg@corprominence.com, or via fax at 787-796-5168. This page (OTCMKTS:PBSV) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.